What is Salspera, Inc.?

Salspera, Inc. is a privately held biopharmaceutical company, a Delaware corporation headquartered at 45 Prospect Street, Cambridge, Massachusetts, co-founded in 2017 by Eddie Moradian, PhD (CEO) and Daniel Saltzman, MD, PhD (CMO). It is developing Saltikva, an investigational oral live-bacteria immunotherapy (an engineered Salmonella carrying the human IL-2 gene) for solid tumors. Saltikva has been studied in an open-label, non-randomized Phase 2 trial in metastatic pancreatic cancer and is not approved for any use by the FDA or any other regulator. SEC EDGAR identifies Salspera, Inc. by CIK 0002084032. Its S-1 is pending and unpriced; a CIK does not establish effectiveness, listing or SEC endorsement.